Global Watchdog
Media And Commentary
A Comparison of Side Effects With Prescription Medication and Marijuana
Global Watchdog is reader-supported, with no advertisers and no government entity to answer to. If you enjoyed this article, you can help keep it coming with a one-time donation or monthly support: Support on PatreonDonate on Ko-fi15 min read
Last updated
Last updated October 25, 2026: fully rewritten with current evidence. The 2014 version of this article compared one prescription drug’s entire warning label against a short list of marijuana side effects and declared a winner. That was rigged, and this replacement says so, rebuilds the comparison category by category from the CDC, the National Academies, and the FDA label, and brings the Georgia and federal law sections current through October 2026.
I first wrote this article in December 2014, when a Bloomberg editorial was praising the “marijuana middle,” Georgia families were fighting for cannabis oil for their children, and the polls sat at about 50-50. A lot of what I wrote then was the conventional wisdom of the moment. Some of it has aged well. Some of it has not, and the structure of the piece itself was the biggest problem: I pasted the side effect list of a single powerful prescription drug, Humira, next to five bullet points about marijuana side effects and concluded that marijuana was “far safer.” That is not a comparison. That is a thumb on the scale.
So here is the honest version, twelve years on. Marijuana in 2026 is a stronger product, a bigger business, and a more complicated legal object than the plant I wrote about in 2014. Prescription drugs, meanwhile, were never one thing, and treating them as one thing was the original sin of the first draft. What follows gives each side its real ledger, good and bad, and then renders verdicts one category at a time, because “which is safer?” has no honest single answer.
The Short Version
- On overdose, marijuana wins and it is not close: there is no documented fatal overdose from cannabis alone, while drug overdoses killed about 80,000 Americans in 2024, most of them involving opioids.
- On other categories the verdict flips. About 3 in 10 people who use cannabis develop cannabis use disorder, per the CDC, and the link between daily high potency use and psychosis is graded “substantial evidence” by the National Academies.
- Humira, the 2014 article’s villain, has mild everyday side effects and rare catastrophic ones, both printed on its FDA label, along with the monitoring system built to catch them. Since 2023, biosimilar competitors have also broken its price monopoly.
- Georgia now runs a licensed medical cannabis program with about 34,500 registered patients, dispensaries, and pharmacy sales. A May 2026 law removed the old THC cap and allows patients 21 and older to vaporize flower. Recreational use is still a crime here, and food products are still banned even for patients.
- Federally, state licensed medical marijuana and FDA approved marijuana products moved to Schedule III in April 2026. Everything else marijuana is still Schedule I, and the broader rescheduling case is paused in front of an administrative law judge.
Table of Contents
What Changed Since 2014
The product changed. The average THC content of cannabis seized by the DEA rose from about 4 percent in 1995 to about 16 percent in 2022, and modern concentrates can reach 90 percent THC. Most of the older research, and most of the 2014 article, described a weaker drug than the one heavy users consume now. Risk figures have to be read against potency: the evidence linking cannabis to addiction and psychosis strengthens as the THC climbs.
A new harm got a name. Cannabis hyperemesis syndrome, a cycle of severe nausea, vomiting, and abdominal pain in frequent users, was a curiosity in 2014. A CDC study published in 2026 counted 199,565 emergency department visits involving the syndrome from January 2023 through May 2026, with the highest rates among 15 to 24 year olds. Part of the recorded rise is better recognition and a new diagnosis code that took effect in October 2025, and honest reporting says so.
The vape era happened. In 2019 and 2020, the lung injury outbreak called EVALI hospitalized 2,807 people and killed 68 in the United States. It was driven overwhelmingly by informal market THC vape cartridges cut with vitamin E acetate. EVALI remains the clearest proof on record that the danger often sits in the unregulated supply chain rather than in the molecule itself.
A gray market grew up beside the legal one. The 2018 Farm Bill’s hemp definition spawned delta-8 THC and other intoxicating hemp products that did not exist when I wrote the original. Georgia answered in 2024 with testing, labeling, age, and licensing rules, and federal law tightened again in late 2025, with staged effective dates running through December 2026.
Marijuana Side Effects: The Ledger, Both Sides
The fairest single source remains the National Academies of Sciences, Engineering, and Medicine, which reviewed more than 10,000 studies and issued graded conclusions in 2017, then restated the public health picture in a 2024 policy report. Here is what that record supports.
What cannabis treats. The Academies found conclusive or substantial evidence that cannabis or oral cannabinoids help chronic pain in adults, chemotherapy induced nausea and vomiting, and patient reported spasticity symptoms in multiple sclerosis. That is a real, if short, list, and no honest article should skip it.
Dependence. The CDC’s current figure is that approximately 3 in 10 people who use cannabis have cannabis use disorder. The risk concentrates in people who start young and in frequent users, and highly concentrated THC products are associated with more severe symptoms. The old talking point of 1 in 10 is out of date.
Mental health. The Academies graded the association between cannabis use and schizophrenia or other psychoses as substantial evidence, with the highest risk among the most frequent users. In the large European EU-GEI study published in The Lancet Psychiatry in 2019, daily use of high potency cannabis was associated with roughly five times the odds of a first psychotic episode compared with never users. The causation debate continues, and the CDC’s wording is more cautious, but the association is consistent and dose dependent, and any article that omits it is selling something.
Driving. The Academies found substantial evidence of increased crash risk. Cannabis slows reaction time and impairs coordination and perception, alcohol multiplies the impairment, and there is no breathalyzer equivalent and no settled blood THC threshold. That enforcement gap is a genuine unsolved problem.
Lungs and heart. Long term smoking is associated with worse respiratory symptoms and more frequent chronic bronchitis, and quitting improves them. The Academies found no evidence linking cannabis smoking to lung cancer. The CDC adds that cannabis raises heart rate and blood pressure immediately after use and could raise the risk of stroke and heart disease; that evidence is association level, strongest as an acute trigger in vulnerable users.
Teens and pregnancy. The CDC warns that cannabis affects memory, learning, attention, and decision making while the brain is still developing, which is why adolescent use carries outsized risk. Use during pregnancy is linked to lower birth weight, a link the Academies graded substantial, and the CDC recommends against use in any form during pregnancy.
The Prescription Side, Fairly: Humira as the Worked Example
The 2014 article treated Humira’s warning label as the profile of all prescription medicine. It is not. Prescription drugs are thousands of products, from acetaminophen to fentanyl, and no single label speaks for the class. But Humira is still a useful worked example, precisely because its label is long and frightening when dumped raw on a reader. Summarized honestly, it tells a more interesting story.
Humira (adalimumab) is a TNF blocker, an injected biologic approved for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and several other serious inflammatory diseases. Those diseases are themselves disabling, which is the first thing the 2014 piece left out: the relevant comparison is never drug versus nothing, it is drug versus the disease untreated.
Its everyday side effects are unglamorous. In the label’s pooled rheumatoid arthritis trials, the most common reactions were upper respiratory infection (17 percent, against 13 on placebo), headache (12 percent), rash (12 percent), sinusitis (11 percent), and injection site reactions (8 percent, against 1 on placebo). Seven percent of patients stopped the drug over adverse reactions, against 4 percent on placebo. Read flat, that is a head cold and a sore injection site for most people.
Its rare side effects are genuinely dangerous. The FDA label carries a boxed warning, its most serious kind, covering two risks. Because Humira suppresses part of the immune system, patients face increased risk of serious infections that can lead to hospitalization or death, including active tuberculosis and invasive fungal infections; patients are tested for latent TB before starting.
The label also warns of lymphoma and other malignancies reported in children and adolescents on TNF blockers, including a rare and usually fatal T cell lymphoma seen mostly in young males with inflammatory bowel disease who were also taking other immunosuppressants. Hepatitis B reactivation, heart failure, and serious allergic reactions round out the warnings. The fair one sentence version: Humira’s common side effects are mild, its rare ones can kill you, and both halves are printed on the same label.
What changed since 2014: for two decades Humira was the best selling drug in the world, at a United States list price that reached roughly $83,000 a year. Amgen’s biosimilar Amjevita launched on January 31, 2023, at least seven more biosimilars followed that July, and discounts in some channels run as deep as 85 to 90 percent off list. The monopoly the price critics of 2014 complained about is broken, even if American pharmacy benefit managers have been slow to pass the savings along.
Category by Category: The Honest Verdicts
Here is the comparison the 2014 article owed its readers: marijuana side effects against prescription drug effects, one category at a time, with a verdict in each row.
| Category | Verdict | Why |
|---|---|---|
| Fatal overdose | Marijuana, clearly | No confirmed fatal overdose from cannabis alone exists in the record. About 80,391 Americans died of drug overdoses in 2024, most involving opioids, above all illicit fentanyl rather than a prescription taken as directed. Overdose is the wrong category in which to attack marijuana, and the right one in which to fear opioids. |
| Dependence | Split, opioids worse | Prescription opioids and sedatives carry physical dependence with lethal overdose and withdrawal risk. Cannabis dependence is real (about 3 in 10 users, per the CDC) but milder and not lethal. Neither side gets a free pass. |
| Long term organ damage | Depends on the drug | Humira’s long term risks are immune risks, infection and malignancy warnings, not classic organ poisoning. Long term cannabis smoking damages airways (chronic bronchitis) without the lung cancer link found for tobacco. Category verdicts that ignore which drug, which dose, and which user are advocacy, not evidence. |
| Psychiatric risk | Prescriptions, marijuana loses this one | The psychosis association is graded substantial evidence, is dose and potency dependent (about five times the odds for daily high potency use in the EU-GEI study), and is strongest for adolescents and people with a family history. This is marijuana’s clearest serious harm. |
| Driving | Both impair | Cannabis raises crash risk, slows reactions, and has no roadside test or agreed blood limit, which makes it the harder enforcement problem. Opioids, benzodiazepines, and sleep medicines carry their own impairment warnings. Impairment is impairment. |
| Drug interactions | Prescriptions, on documentation | An approved drug’s interactions are mapped in its label. Cannabis interacts with alcohol and sedatives, and THC and CBD affect the liver enzymes that process many common prescriptions. Those interactions are real and far less studied, because the research was illegal for decades. |
| Dosing and quality control | Prescriptions, by a mile | A Humira pen is a labeled, tested dose made under FDA manufacturing rules, and Georgia’s licensed medical products are batch tested under state rules. In the illicit market, quality control collapses entirely, and EVALI showed where that ends. Edibles add their own trap: a one to three hour delayed onset that tempts users to redose and overshoot. |
Bottom Line
On marijuana side effects versus prescription side effects, there is no class winner, and there never was. Marijuana has no lethal overdose pathway, and it has a real bill of harms, dependence, psychosis risk, bronchitis, impaired driving, and a vomiting syndrome that fills emergency rooms, and that bill grows with potency and frequency. A biologic like Humira has mild everyday side effects, a small and real chance of catastrophic ones, and an entire monitoring system built to catch them. Anyone who gives you a simpler answer than that is selling you something.
Georgia in 2026: From Haleigh’s Hope to Flower
The original article ended with Georgia politics in 2014, predicting action in early 2015. The prediction was right and the timeline was a fantasy. Here is the actual arc.
2015: possession legal, supply illegal. Haleigh’s Hope Act, signed that April, created the Low THC Oil Patient Registry and decriminalized possession of up to 20 fluid ounces of oil at no more than 5 percent THC for registered patients with severe conditions. It created no legal way to make or buy the oil in Georgia. Families could legally hold a medicine they could not legally obtain.
2019: production, on paper. Georgia’s Hope Act created the Georgia Access to Medical Cannabis Commission and authorized in state cultivation and dispensing, keeping the 5 percent cap. The Class 1 production licenses were not awarded until July 2021, to Trulieve GA and Botanical Sciences.
2023: the first sales, eight years after legalization. Trulieve opened Georgia’s first dispensaries in April 2023, in Macon and Marietta, selling oils, tinctures, capsules, and topicals. That October, Georgia became the first state in the nation to license independent pharmacies to sell low THC oil, and about 120 pharmacies signed on, putting most Georgians within a half hour’s drive of a dispensing point. A month later the DEA warned those pharmacies that because THC remained Schedule I, a DEA registered pharmacy could lawfully dispense only Schedule II to V drugs. The federal order of April 2026, described below, partly reshapes that friction for state licensed medical marijuana, though the pharmacy question specifically has not been publicly resolved.
2026: the Putting Georgia’s Patients First Act. Governor Kemp signed SB 220 on May 12, 2026, effective July 1. It renamed the program from Low THC Oil to medical cannabis, removed the 5 percent THC cap (patients may now possess up to 12,000 milligrams of THC in total), authorized vaporization of flower for patients 21 and older while keeping smoking banned, broadened the qualifying conditions, adding lupus and expanding Crohn’s disease to inflammatory bowel disease, and gave out of state patients 45 day reciprocity. Food products remain prohibited even for patients: no legal edibles or gummies in Georgia’s program. The registry stands at roughly 34,500 active patients.
What is still illegal. Recreational use, full stop. Possession of an ounce or less is a misdemeanor carrying up to a year in jail; more than an ounce is a felony carrying one to ten years. Atlanta and several other Georgia cities have locally decriminalized small amounts, and home cultivation and smoking remain prohibited for everyone, patients included.
The Federal Picture in 2026: Halfway Out of Schedule I
The strangest development of all is federal. After President Trump’s December 2025 executive order directing the Attorney General to finish the job, the Justice Department issued a final rule that took effect April 28, 2026: marijuana in FDA approved drug products, and marijuana under a state medical marijuana license, is now Schedule III. State licensed medical businesses also escape the Section 280E tax penalty that applies to Schedule I and II trafficking.
Everything else marijuana, which includes all recreational marijuana, remains Schedule I. The broader case for moving all of it went through eleven days of administrative hearings in June and July 2026, and on September 29, 2026 the chief administrative law judge stayed the proceeding while he decides whether a critical GAO report on agency scheduling procedures belongs in the record. As of late October 2026 there is no recommended decision and no final ruling, and analysts put completion as late as the third quarter of 2027. So the honest one liner for 2026 is: medical marijuana under a state license is federally Schedule III today, and the rest is paused mid process.
Frequently Asked Questions
Is marijuana addictive? It can be. The CDC puts cannabis use disorder at approximately 3 in 10 people who use it, with the risk concentrated in those who start during adolescence and in frequent users, and with high THC products associated with more severe symptoms. Cannabis withdrawal is real, though it is not medically dangerous the way alcohol or benzodiazepine withdrawal can be.
What is cannabis hyperemesis syndrome? A cycle of severe nausea, vomiting, and abdominal pain that strikes some frequent users and sends them to emergency departments repeatedly; it resolves when cannabis use stops. A CDC study counted 199,565 emergency department visits involving it from January 2023 through May 2026, with rates highest among 15 to 24 year olds.
Is medical marijuana legal in Georgia now? Yes, under a regulated program: a physician certifies a qualifying condition, the patient registers with the Department of Public Health, and products are bought from licensed dispensaries or participating pharmacies. Since July 1, 2026, patients 21 and older may also vaporize flower. Smoking, edibles, home growing, and recreational use remain illegal.
Did the federal government legalize marijuana in 2026? No. A final rule effective April 28, 2026 moved state licensed medical marijuana and FDA approved marijuana products to Schedule III, which matters for research, taxes, and pharmacy law. Recreational marijuana remains Schedule I, and the broader rescheduling case is stayed in front of an administrative law judge with no decision issued. Professor Winston Wants to Know Our resident watchdog is taking the temperature of the room. Georgia widened its medical cannabis program in 2026. What should the state do next? One tap, no account or email needed. Results are shown after you vote. Want to say more? The comments below are open.
This article is general information about published research and current law, not medical advice. Decisions about any drug, prescribed or otherwise, belong between you and your own physician.
Sources
- National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids (2017), and its 2024 policy follow up.
- Centers for Disease Control and Prevention, Cannabis Health Effects and Cannabis and Pregnancy.
- CDC, Morbidity and Mortality Weekly Report (2026), cannabis hyperemesis syndrome emergency department visits.
- U.S. Food and Drug Administration, Humira (adalimumab) prescribing information, via DailyMed.
- Di Forti and colleagues, EU-GEI study, The Lancet Psychiatry (2019), on daily high potency use and first episode psychosis.
- Marijuana Policy Project, Georgia Medical Cannabis Law Summary (SB 220, 2026).
- The Marijuana Herald, federal rescheduling status tracker, updated October 21, 2026.
Keep the watchdog independent
If this article saved you money, time, or a headache, if you enjoyed it, or if you want to support local investigative journalism, you can buy me a coffee by card. No account needed, and Ko-fi takes no cut, so it all goes to the work.
Prefer steady support? Join the Patreon for monthly backing.
